A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Saved in:
| Title: | A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis. |
|---|---|
| Authors: | Liu, Yaxin1 (AUTHOR), Wang, Wei2 (AUTHOR), Yin, Rutie3 (AUTHOR), Zhang, Youzhong4 (AUTHOR), Zhang, Yu5 (AUTHOR), Zhang, Keqiang6 (AUTHOR), Pan, Hongming7 (AUTHOR), Wang, Ke8 (AUTHOR), Lou, Ge9 (AUTHOR), Li, Guiling10 (AUTHOR), Zhang, Ruyan1 (AUTHOR), Li, Kun1 (AUTHOR), Rao, Jing11 (AUTHOR), Zhang, Ben11 (AUTHOR), Wang, Yuting11 (AUTHOR), Wang, Quanren11 (AUTHOR), Gao, Yunong2 (AUTHOR) gao_fuke@126.com, Li, Huiping1 (AUTHOR) huipingli2012@hotmail.com |
| Source: | BMC Medicine. 9/29/2023, Vol. 21 Issue 1, p1-10. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17417015 |
|---|---|
| DOI: | 10.1186/s12916-023-03046-8 |
